儿童期生长激素治疗与SGA成人停药后12年代谢及心血管风险随访
该研究对167名曾接受生长激素治疗的SGA成人进行停药后12年纵向随访,并在约30岁时与219名未治疗成人比较代谢及心血管健康。结果显示SGA-GH成人β细胞功能维持正常、胰岛素敏感性升高,多数代谢及心血管参数与SGA-S及AGA成人相似,但瘦体重较低且血脂水平较高。
要点
- SGA-GH成人停药后12年β细胞功能维持正常,胰岛素敏感性升高。
- 约30岁时SGA-GH成人的代谢及心血管参数与SGA-S及AGA成人相似。
- SGA-GH成人瘦体重较低,且所有SGA组血脂水平均较高。
核心结论
- 约30岁时,SGA-GH成人的代谢及心血管健康特征与未治疗的SGA或AGA成人相似,提示对矮身材SGA儿童使用生长激素具有长期代谢及心血管安全性。
研究设计与样本
- 纵向研究纳入167名曾接受生长激素治疗的SGA成人,随访停药后12年。
- 在约30岁时与219名未治疗成人比较:127名SGA(含持续矮身材SGA-S或自发追赶至正常成人身高SGA-CU)及92名AGA成人。
主要发现
- 12年随访期间,SGA-GH成人β细胞功能维持正常(与停药时比较差异p=0·157),胰岛素敏感性升高(p=0·002)。
- 12年随访期间,SGA-GH成人脂肪质量(p<0·001)、总胆固醇(p<0·001)和血压(p<0·001)升高。
- 约30岁时,SGA-GH成人胰岛素敏感性(p=0·242)、脂肪质量(p=0·449)、总胆固醇(p=0·616)、收缩压(p=0·523)和舒张压(p=0·538)与SGA-S成人相似。
- 约30岁时,SGA-GH成人瘦体重低于AGA成人(估计边际均值44·67 kg [95%CI 43·54-45·80] vs 47·65 kg [46·39-48·92]),总胆固醇较高(4·75 mmol/L [4·55-4·95] vs 4·33 mmol/L [4·13-4·5])。
- SGA-GH成人内脏脂肪(p=0·107)、皮下脂肪(p=0·244)、肝脏脂肪分数(p=0·104)、收缩压(0·927)和舒张压(0·737)与所有对照组相似。
关键数值与推荐
- SGA-GH成人约30岁时胰岛素敏感性、脂肪质量、总胆固醇、收缩压和舒张压与SGA-S成人相比差异均无统计学意义(p值分别为0·242、0·449、0·616、0·523、0·538)。
- SGA-GH成人瘦体重估计边际均值44·67 kg(95%CI 43·54-45·80),AGA成人为47·65 kg(95%CI 46·39-48·92)。
- SGA-GH成人总胆固醇4·75 mmol/L(95%CI 4·55-4·95),AGA成人为4·33 mmol/L(95%CI 4·13-4·5)。
临床怎么用
- 对矮身材SGA儿童使用生长激素治疗时,可参考该长期随访结果评估代谢及心血管安全性。
- 停药后仍需关注瘦体重及血脂水平,尤其所有SGA成人均存在血脂偏高倾向。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Childhood growth hormone treatment has been associated with increased cardiovascular mortality and morbidity in adults born small for gestational age (SGA) compared with the general population, but these risks have not been compared with untreated control groups. We aimed to investigate longitundinal metabolic and cardiovascular health in adults born SGA after cessation of growth hormone treatment. METHODS: We longitudinally investigated the metabolic and cardiovascular health profile of 167 adults born SGA and previously treated with growth hormone during the 12 years after growth hormone cessation. Metabolic and cardiovascular parameters were assessed with the frequently sampled intravenous glucose tolerance test, serum lipids and blood pressure were measured, body composition was determined by dual-energy x-ray absorptiometry, and visceral fat was measured by MRI. At approximately age 30 years, we compared the metabolic and cardiovascular health profile of adults born SGA and previously treated with growth hormone (SGA-GH) with 219 untreated adults: 127 born SGA with either persistent short stature (SGA-S) or spontaneous catch-up to typical adult stature (SGA-CU), and 92 born appropriate for gestational age. FINDINGS: During 12 years of follow-up, SGA-GH adults maintained normal β-cell function (p=0·157 for the difference from growth hormone cessation to 12-year follow-up) and showed an increase in insulin sensitivity (p=0·002), fat mass (p<0·001), total cholesterol (p<0·001), and blood pressure (p<0·001). By around age 30 years, these parameters reached similar levels to those in SGA-S adults (insulin sensitivity p=0·242; fat mass p=0·449; total cholesterol p=0·616; systolic blood pressure p=0·523; diastolic blood pressure p=0·538). By around age 30 years, SGA-GH adults also had similar metabolic and cardiovascular health parameters to adults born appropriate for gestational age, with the exception of lower lean body mass (estimated marginal mean 44·67 kg [95% CI 43·54-45·80] in SGA-GH adults vs 47·65 kg [46·39-48·92] in adults born appropriate for gestational age) and higher concentrations of adverse serum lipids, such as cholesterol (4·75 mmol/L [4·55-4·95] vs 4·33 mmol/L [4·13-4·5]), which were present in all groups born SGA. Abdominal adiposity (visceral adipose tissue p=0·107; subcutaneous adipose tissue: p=0·244), liver fat fraction (p=0·104), and blood pressure (systolic blood pressure 0·927; diastolic blood pressure: 0·737) were similar between SGA-GH adults and all control groups. INTERPRETATION: At approximately age 30 years, SGA-GH adults had a similar metabolic and cardiovascular health profile to untreated adults born SGA or appropriate for gestational age, indicating long-term metabolic and cardiovascular safety of growth hormone treatment for children born SGA with short stature. FUNDING: Novo Nordisk.
引用
- Goedegebuure WJ, van der Steen M, Smeets CCJ, et al. Childhood growth hormone treatment and metabolic and cardiovascular risk in adults born small for gestational age after growth hormone cessation in the Netherlands: a 12-year follow-up study. Lancet Child Adolesc Health. 2022. PMID: 36122581. doi:10.1016/S2352-4642(22)00240-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。